Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leriglitazone in pediatric Rett syndrome
2024-514684-26-00Phase 2Completed
- Sponsor
- Minoryx Therapeutics
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Rett syndrome (RTT) comparing Leriglitazone with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Oct 2024; status: completed.
02
Drugs
leriglitazone
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on 2024-514684-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514684-26-00.